<DOC>
	<DOCNO>NCT01460979</DOCNO>
	<brief_summary>The purpose study determine activity , tolerability safety Temsirolimus woman ovarian cancer progress previous platinum chemotherapy alternatively within 6 month completion therapy advance endometrial carcinoma .</brief_summary>
	<brief_title>Efficacy , Tolerability , Safety Temsirolimus Women With Platinum-refractory Ovarian Carcinoma Advanced Endometrial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Genital Diseases , Female</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Before performance study specific action assessment patient inform , sign write consent willing follow requirement concern treatment followup.Comment : Procedures accord common clinical routine perform give write informed consent may use purpose screen procedure initial medical assessment long procedure follow protocol . Required : negative pregnancy test fertile woman Stratum A Ovarian Cancer : Histologically confirm Ovarian Cancer Platinrefractory relapse disease : progression within platinbased chemotherapy within 6 month completion platinbased chemotherapy Prior treatment taxanebased scheme minimum one measurable nonmeasurable tumor lesion ( accord RECIST 1.1 criterion ) Not 2 previous chemotherapy cytostatic therapy ( i.e . monoclonal antibody , cytokine , signal transduction inhibitor ) Stratum B Endometrian Cancer : Histologically confirm Endometrian Cancer Advanced ( International Federation Gynaecology Obstetrics ( FIGO ) III IV ) relapse disease amenable potentially curative treatment local surgery and/or radiation therapy Prior endocrine therapy allow Prior adjuvant chemotherapy allow Minimum one measurable nonmeasurable tumor lesion ( accord RECIST 1.1 criterion ) ECOG &gt; 2 Prior therapy mammalian target rapamycin ( mTOR ) Inhibitor Cytostatic therapy ( i.e . monoclonal antibody , cytokine , signal transduction inhibitor ) , cytotoxical chemotherapy endocrine therapy radiation time Current recent treatment another study drug and/or participation another clinical study within 28 day prior first dose study treatment Chemotherapy cytostatic therapy ( i.e . monoclonal antibody , cytokine , signal transduction inhibitor ) radiation within 28 day prior start study treatment Known suppose hypersensitivity compare study medication Acute chronical infection Second malignancy influence prognosis patient Inadequate renal function ( Creatinin &gt; 1.5 x Upper Limit Normal ( ULN ) ) Inadequate liver function ( aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , gammaGlutamyl transpeptidase ( GGT ) &gt; 2.5 x ULN &gt; 5.0 x ULN presence liver metastasis ; Bilirubin &gt; 1.5 x ULN ) Platelets &lt; 100.000 /μl ; Absolute Neutrophil Count ( ANC ) &lt; 1.500 /μl Cachectic patient weight &lt; 45kg Patients need parenteral nutrition Patients ileus within last 28 day One follow disease within 12 month prior first study treatment : myocardial infarction , severe/unstable angina , bypass surgery coronar peripheral vessel , symptomatic heart insufficiency , cerebrovascular insult , transient ischemic attack ( TIA ) , pulmonary embolism , deep venous thrombosis , thromboembolic event Current treatment Cytochrome P450 3A4 ( CYP3A4 ) Inhibitors ( i.e . protease inhibitor , antimycotic , calcium channel blocker , macrolide antibiotic , Cimetidine ) inductor ( i.e . Carbamazepin , Phenobarbital , Phenytoin , Rifampicin , amber ) Uncontrolled hypertension ( &gt; 150/100 mmHg despite optimal medicinal treatment ) Current cardiac arrhythmia ( Common Terminology Criteria Adverse Events National Cancer Institute ( NCI CTCAE ) grade ≥ 2 ) , atrial fibrillation , prolongation QTc &gt; 470 msec Left ventricular ejection fraction ( LVEF ) ≤ 50 % define echocardiogram NCI CTCAE grade 3 hemorrhage within 4 week prior begin treatment Symptoms indicate brain metastasis , spinal cord compression give new indication brain leptomeningeal metastases Human immunodeficiency virus ( HIV ) positive manifest Acquired Immune Deficiency Syndrome ( AIDSdisease ) Patients severe disease represent inadequate risk study participation Applicable patient hysterectomy and/or bilateral adnexectomy prior start study . lactation potential fertile woman without adequate contraception ( potential fertile woman must use one follow adequate contraception : complete abstinence , intrauterine spiral another method failure quote &lt; 1 % per year ) life expectancy &lt; 3 month neurological psychiatric disease drug alcohol abuse suppose adequate comprehension consequently effective consent study participation acceptable compliance study predictable problem compliance appointment examination</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Endometrial Carcinoma</keyword>
	<keyword>Temsirolimus</keyword>
</DOC>